Deploying an artificial intelligence-based online search tool to increase patients' access to and understanding of solid tumor gastrointestinal clinical trials.

backgroundThe number and complexity of clinical trials is growing, making finding and accessing trials increasingly challenging. A key barrier to increasing recruitment efficiency is patients' low awareness of trials as an option. They rarely hear about trials from oncologists, unless these are based at a research center, which introduces trial population biases. Even if patients decide to search for trial information on their own, it is difficult for laypeople to understand. Trial search tools exist, but have multiple shortcomings: complex navigation, limited search functionality, data too complex for non-specialists, and next steps unclear.

methodsAccess to trials via a novel trial search tool using technology, including artificial intelligence (AI), to restructure trial information and match patients to trials was the focus of this study. We focused on 6 gastrointestinal cancers for evaluating the search tool's AI model in which their trial information was restructured based on key eligibility differentiators identified. Research participants were recruited with the support of patient associations leveraging social media. They were asked to complete a survey evaluating an established tool and the novel tool to find trials relevant for them. They assessed aspects of the tools' usability on 5-level Likert scales.

resultsSurvey respondents had a base level of awareness of trials, with patient associations and the internet as leading information sources. The novel tool made it easier to find trials, led to an improvement in ease of understanding information presented and provided more clarity on what the next steps towards enrollment would be. Overall, this led to higher patient satisfaction.

conclusionsNovel patient-focused tools can unlock trial access for all patients. Democratizing trial information will not only increase trial accrual, but also patient satisfaction while reducing disparities. This tool could also be of value for academic or community oncologists who face similar issues when navigating trials for patients.